Hepatotoxicity and Ceritinib (Studies and Clinical Data)
Studies and Data
• ASCEND Trials: In the ASCEND clinical trials, which evaluated ceritinib’s efficacy and safety, hepatotoxicity was among the most commonly reported adverse effects. Elevations in ALT and AST were observed in a significant percentage of patients, leading to dose modifications in some cases .
• Real-World Data: Post-marketing surveillance and real-world studies have confirmed the findings of clinical trials, indicating that hepatotoxicity is a
common concern and highlighting the importance of regular liver function monitoring